Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Simultaneous Determination of Celecoxib, Erlotinib, and its Metabolite Desmethyl-Erlotinib (OSI-420) in Rat Plasma by Liquid chromatography/Tandem Mass Spectrometry with Positive/Negative Ion-Switching Electrospray Ionisation.
Thappali SR, Varanasi K, Veeraraghavan S, Arla R, Chennupati S, Rajamanickam M, Vakkalanka S, Khagga M. Thappali SR, et al. Among authors: vakkalanka s. Sci Pharm. 2012 Jul-Sep;80(3):633-46. doi: 10.3797/scipharm.1205-09. Epub 2012 Jun 18. Sci Pharm. 2012. PMID: 23008811 Free PMC article.
Design, Synthesis, and Identification of Silicon Incorporated Oxazolidinone Antibiotics with Improved Brain Exposure.
Seetharamsingh B, Ramesh R, Dange SS, Khairnar PV, Singhal S, Upadhyay D, Veeraraghavan S, Viswanadha S, Vakkalanka S, Reddy DS. Seetharamsingh B, et al. Among authors: vakkalanka s. ACS Med Chem Lett. 2015 Oct 26;6(11):1105-10. doi: 10.1021/acsmedchemlett.5b00213. eCollection 2015 Nov 12. ACS Med Chem Lett. 2015. PMID: 26617962 Free PMC article.
Targeting Cancer Cells and Tumor Microenvironment in Preclinical and Clinical Models of Hodgkin Lymphoma Using the Dual PI3Kδ/γ Inhibitor RP6530.
Locatelli SL, Careddu G, Serio S, Consonni FM, Maeda A, Viswanadha S, Vakkalanka S, Castagna L, Santoro A, Allavena P, Sica A, Carlo-Stella C. Locatelli SL, et al. Among authors: vakkalanka s. Clin Cancer Res. 2019 Feb 1;25(3):1098-1112. doi: 10.1158/1078-0432.CCR-18-1133. Epub 2018 Oct 23. Clin Cancer Res. 2019. PMID: 30352904
A First-in-human Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor, in Patients With Relapsed/Refractory Hematologic Malignancies: Results From the European Study.
Carlo-Stella C, Delarue R, Scarfo L, Barde PJ, Nair A, Locatelli SL, Morello L, Magagnoli M, Vakkalanka S, Viswanadha S, Ferreri AJM. Carlo-Stella C, et al. Among authors: vakkalanka s. Clin Lymphoma Myeloma Leuk. 2020 Feb;20(2):78-86. doi: 10.1016/j.clml.2019.10.013. Epub 2019 Oct 23. Clin Lymphoma Myeloma Leuk. 2020. PMID: 31761713 Clinical Trial.
Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma.
Huen A, Haverkos BM, Zain J, Radhakrishnan R, Lechowicz MJ, Devata S, Korman NJ, Pinter-Brown L, Oki Y, Barde PJ, Nair A, Routhu KV, Viswanadha S, Vakkalanka S, Iyer SP. Huen A, et al. Among authors: vakkalanka s. Cancers (Basel). 2020 Aug 15;12(8):2293. doi: 10.3390/cancers12082293. Cancers (Basel). 2020. PMID: 32824175 Free PMC article.
26 results